Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPO 14-1 first-in-human dose escalation study
NCT05628961Phase 1Completed
- Sponsor
- SRI International
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HOPO 14-1 in Radionuclide internal contamination (RIC) (7 cohorts), sponsored by SRI International. Primary endpoints: Adverse Events at 14 days, Drug-Related Adverse Events at 14 days and 2 more. Started Mar 2023; status: completed.
02
Drugs
HOPO 14-1
03
Conditions
Radionuclide internal contamination (RIC)
Beyond the preview
Go deeper on NCT05628961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628961.